Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:1581-1590
Published online before print March 12, 2007, doi: 10.1161/CIRCULATIONAHA.106.669697
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
115/12/1581    most recent
CIRCULATIONAHA.106.669697v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eckle, T.
Right arrow Articles by Eltzschig, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eckle, T.
Right arrow Articles by Eltzschig, H. K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Acute myocardial infarction
Right arrow Receptor pharmacology
Right arrow Other Vascular biology
Right arrow Animal models of human disease

(Circulation. 2007;115:1581-1590.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

Cardioprotection by Ecto-5'-Nucleotidase (CD73) and A2B Adenosine Receptors

Tobias Eckle, MD; Thomas Krahn, MD; Almut Grenz, MD; David Köhler, BS; Michel Mittelbronn, MD; Catherine Ledent, PhD; Marlene A. Jacobson, PhD; Hartmut Osswald, MD; Linda F. Thompson, PhD; Klaus Unertl, MD; Holger K. Eltzschig, MD, PhD

From the Department of Anesthesiology and Intensive Care Medicine (T.E., D.K., K.U., H.K.E.), Department of Pharmacology and Toxicology (A.G., H.O.), and Institute of Brain Research (M.M.), Tübingen University Hospital, Tübingen, Germany; Bayer HealthCare AG, Wuppertal, Germany (T.K.); Institut de Recherches en Biologie Humaine et Moleculaire, Université Libre de Bruxelles, Brussels, Belgium (C.L.); Department of Pharmacology, Merck Research Laboratories, West Point, Pa (M.A.J.); and Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City (L.F.T.).

Correspondence to Holger K. Eltzschig, MD, PhD, Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Hoppe-Seyler-Str 3, D-72076 Tübingen, Germany. E-mail heltzschig{at}partners.org

Received October 13, 2006; accepted January 17, 2007.

Background— Ecto-5'-nucleotidase (CD73)–dependent adenosine generation has been implicated in tissue protection during acute injury. Once generated, adenosine can activate cell-surface adenosine receptors (A1AR, A2AAR, A2BAR, A3AR). In the present study, we define the contribution of adenosine to cardioprotection by ischemic preconditioning.

Methods and Results— On the basis of observations of CD73 induction by ischemic preconditioning, we found that inhibition or targeted gene deletion of cd73 abolished infarct size-limiting effects. Moreover, 5'-nucleotidase treatment reconstituted cd73–/– mice and attenuated infarct sizes in wild-type mice. Transcriptional profiling of adenosine receptors suggested a contribution of A2BAR because it was selectively induced by ischemic preconditioning. Specifically, in situ ischemic preconditioning conferred cardioprotection in A1AR–/–, A2AAR–/–, or A3AR–/– mice but not in A2BAR–/– mice or in wild-type mice after inhibition of the A2BAR. Moreover, A2BAR agonist treatment significantly reduced infarct sizes after ischemia.

Conclusions— Taken together, pharmacological and genetic evidence demonstrate the importance of CD73-dependent adenosine generation and signaling through A2BAR for cardioprotection by ischemic preconditioning and suggests 5'-nucleotidase or A2BAR agonists as therapy for myocardial ischemia.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
CirculationHome page
T. Eckle, D. Kohler, R. Lehmann, K. C. El Kasmi, and H. K. Eltzschig
Hypoxia-Inducible Factor-1 Is Central to Cardioprotection: A New Paradigm for Ischemic Preconditioning
Circulation, July 8, 2008; 118(2): 166 - 175.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Mikhailov, A. Sokolovskaya, G. G. Yegutkin, H. Amdahl, A. West, H. Yagita, R. Lahesmaa, L. F. Thompson, S. Jalkanen, D. Blokhin, et al.
CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis
J. Immunol., July 1, 2008; 181(1): 464 - 475.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. C. Morote-Garcia, P. Rosenberger, J. Kuhlicke, and H. K. Eltzschig
HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak
Blood, June 15, 2008; 111(12): 5571 - 5580.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X. Xu, J. Fassett, X. Hu, G. Zhu, Z. Lu, Y. Li, J. Schnermann, R. J. Bache, and Y. Chen
Ecto-5'-Nucleotidase Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction
Hypertension, June 1, 2008; 51(6): 1557 - 1564.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Takedachi, D. Qu, Y. Ebisuno, H. Oohara, M. L. Joachims, S. T. McGee, E. Maeda, R. P. McEver, T. Tanaka, M. Miyasaka, et al.
CD73-Generated Adenosine Restricts Lymphocyte Migration into Draining Lymph Nodes
J. Immunol., May 1, 2008; 180(9): 6288 - 6296.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
J. M. DOWNEY, T. KRIEG, and M. V. COHEN
Mapping Preconditioning's Signaling Pathways: An Engineering Approach
Ann. N.Y. Acad. Sci., March 1, 2008; 1123(1): 187 - 196.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Eckle, M. Faigle, A. Grenz, S. Laucher, L. F. Thompson, and H. K. Eltzschig
A2B adenosine receptor dampens hypoxia-induced vascular leak
Blood, February 15, 2008; 111(4): 2024 - 2035.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Jalkanen and M. Salmi
VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation
Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 18 - 26.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Grenz, H. Zhang, J. Weingart, S. von Wietersheim, T. Eckle, J. Schnermann, C. Kohle, D. Kloor, C. H. Gleiter, V. Vallon, et al.
Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia
Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1501 - F1511.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Kohler, T. Eckle, M. Faigle, A. Grenz, M. Mittelbronn, S. Laucher, M. L. Hart, S. C. Robson, C. E. Muller, and H. K. Eltzschig
CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia/Reperfusion Injury
Circulation, October 16, 2007; 116(16): 1784 - 1794.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Eckle, L. Fullbier, M. Wehrmann, J. Khoury, M. Mittelbronn, J. Ibla, P. Rosenberger, and H. K. Eltzschig
Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury
J. Immunol., June 15, 2007; 178(12): 8127 - 8137.
[Abstract] [Full Text] [PDF]